China, Aug. 26 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and safety of tacrolimus sustained-release capsules as initial therapy in Chinese kidney transplant patients with CYP3A5 *3/*3 genotype'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600130790
Registration Time: 2026/08/25
Type: Observational study
Primary Sponsor: The Affiliated Hospital, Sun Yat-Sen University
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=245490
Published by HT Digital Content Services with permission from Health Daily Digest....